Associate Director, Drug Delivery and Biomaterials, Allergan
Development of Sustained Release Peptide Implants for the Back of the Eye
Ophthalmology continues to be a growth market driven by increasing aging as well as diabetic populations. Posterior vision threatening diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), are currently managed with ranibizumab (Lucentis®) and more recently, aflibercept (Eylea®). Although offering good therapeutic treatment, these therapies are far from being optimal, as they require frequent injections into the vitreous, and are often comprised by poor patient adherence. Extensive efforts are underway in ophthalmology to improve the therapies with drug delivery products that offer local and sustained efficacy while reducing systemic exposure and potential issues with peaks and valleys of drug levels in the target ocular tissues.
This presentation is designed to describe the development of a sustained release peptide implant formulation for the back of the eye. Key development challenges and considerations will be discussed.